MarketInOut Stock Screener Log In | Sign Up
 

Ocugen Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Ocugen Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization255.32 mln
Float331 mln
Earnings Date11/04/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-3.82
Highly reliable

Relative Strength

10 / 100
Significantly lagging

Pre-Tax Margin

-1,786%
Severely loss-making

ROE

1,688
Extraordinary

Altman Z-Score

-5.69
Deeply distressed

Business Description

Ocugen is a Pennsylvania-based medical company founded in 2013 that develops treatments for eye diseases and infectious illnesses. Its most advanced work focuses on gene therapies targeting inherited retinal conditions such as retinitis pigmentosa and macular degeneration, with several candidates currently in clinical trials. The company is also working on treatments for knee cartilage damage and a range of vaccines, including those for COVID-19 and seasonal flu, supported by partnerships with research institutions and international manufacturers.

Key Fundamentals

EPS-0.26
ROE1,688
RPS0.01
ROIC-124
ROA-122
Interest Cover-8.16
EBITDA, mln-71.64
EV / EBITDA-4.70
EV / EBIT-4.59
Revenue, mln4.58
EV / Revenue73.51

Quote Details

Last 0.7397
Change -0.0503 (-6.37%)
Open 0.7951
Volume 8,455,657
Turnover 6,254,650
Average Volume 6,610,858

Financial Ratios

Pre-Tax Profit Margin-1,786
Current Ratio0.80
Price / Sales73.59

Financial Strength

Altman Z-Score-5.69
Piotroski F-Score 3 / 9
Beneish M-Score-3.82
Short Ratio11.75
Short % of Float30.09

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -5.2% 16 / 100   
1 Month -26.03% 14 / 100   
2 Months -44.38% 10 / 100   
6 Months -55.44% 11 / 100   
1 Year -51.01% 18 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog